87 related articles for article (PubMed ID: 27173015)
1. Combination chemotherapy with 5-fluorouracil and dacarbazine in advanced medullary thyroid cancer, a possible alternative?
Marchand L; Nozières C; Walter T; Descotes F; Decaussin-Petrucci M; Joly MO; Lapras V; Bournaud C; Borson-Chazot F
Acta Oncol; 2016 Aug; 55(8):1064-6. PubMed ID: 27173015
[No Abstract] [Full Text] [Related]
2. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Welin S; Sorbye H; Sebjornsen S; Knappskog S; Busch C; Oberg K
Cancer; 2011 Oct; 117(20):4617-22. PubMed ID: 21456005
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ
Oncology; 2016; 90(6):339-46. PubMed ID: 27207748
[TBL] [Abstract][Full Text] [Related]
4. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
5. MGMT methylation in glioblastoma: tale of the tail.
Shah N; Schroeder B; Cobbs C
Neuro Oncol; 2015 Jan; 17(1):167-8. PubMed ID: 25395464
[No Abstract] [Full Text] [Related]
6. Prime time for molecular marker diagnostics in neuro-oncology.
Weller M; Stupp R
Curr Opin Neurol; 2012 Dec; 25(6):743-4. PubMed ID: 23041956
[No Abstract] [Full Text] [Related]
7. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Hegi ME; Stupp R
Neuro Oncol; 2015 Nov; 17(11):1425-7. PubMed ID: 26374690
[No Abstract] [Full Text] [Related]
8. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
DeAngelis LM
J Clin Oncol; 2009 Dec; 27(35):5861-2. PubMed ID: 19901101
[No Abstract] [Full Text] [Related]
10. Efficacy of temozolomide in a central nervous system relapse of neuroblastoma with O 6 -methylguanine methyltransferase (MGMT) promoter methylation.
Yamada A; Moritake H; Shimonodan H; Yokogami K; Takeshima H; Marutsuka K; Nunoi H
J Pediatr Hematol Oncol; 2013 Jan; 35(1):e38-41. PubMed ID: 23042021
[TBL] [Abstract][Full Text] [Related]
11. Thyroid cancer in 2015: Molecular landscape of thyroid cancer continues to be deciphered.
Nikiforov YE
Nat Rev Endocrinol; 2016 Feb; 12(2):67-8. PubMed ID: 26668120
[No Abstract] [Full Text] [Related]
12. Primary RET-mutated lung neuroendocrine carcinoma in MEN2B: response to RET-targeted therapy.
Geiger JL; Chiosea SI; Challinor SM; Nikiforova MN; Bauman JE
Endocr Relat Cancer; 2015 Oct; 22(5):L19-22. PubMed ID: 26285607
[No Abstract] [Full Text] [Related]
13. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
Amatu A; Sartore-Bianchi A; Moutinho C; Belotti A; Bencardino K; Chirico G; Cassingena A; Rusconi F; Esposito A; Nichelatti M; Esteller M; Siena S
Clin Cancer Res; 2013 Apr; 19(8):2265-72. PubMed ID: 23422094
[TBL] [Abstract][Full Text] [Related]
14. Emergence of Resistant Clones in Medullary Thyroid Cancer May Not Be Rescued by Subsequent Salvage Highly Selective Rearranged During Transfection-Inhibitor Therapy.
Bruce JY; Bible KC; Chintakuntlawar AV
Thyroid; 2021 Feb; 31(2):332-333. PubMed ID: 32664802
[No Abstract] [Full Text] [Related]
15. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).
Nocera M; Baudin E; Pellegriti G; Cailleux AF; Mechelany-Corone C; Schlumberger M
Br J Cancer; 2000 Sep; 83(6):715-8. PubMed ID: 10952773
[TBL] [Abstract][Full Text] [Related]
16. Selpercatinib.
Am J Health Syst Pharm; 2020 Oct; 77(22):1818-1821. PubMed ID: 32930710
[No Abstract] [Full Text] [Related]
17. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.
Kumarasamy VM; Shin YJ; White J; Sun D
BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103
[TBL] [Abstract][Full Text] [Related]
18. [MEN 2A with double mutation in RET gene: Ectopic ACTH production in medullary thyroid carcinoma].
Ares J; Díaz-Naya L; Martín-Nieto A; Pertierra J
Med Clin (Barc); 2016 May; 146(9):419-20. PubMed ID: 26724871
[No Abstract] [Full Text] [Related]
19. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With
Kim J; Bradford D; Larkins E; Pai-Scherf LH; Chatterjee S; Mishra-Kalyani PS; Wearne E; Helms WS; Ayyoub A; Bi Y; Sun J; Charlab R; Liu J; Zhao H; Liang D; Ghosh S; Philip R; Pazdur R; Theoret MR; Beaver JA; Singh H
Clin Cancer Res; 2021 Oct; 27(20):5452-5456. PubMed ID: 34045295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
